Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

Presentation TCT 2020

TCT 449: Direct Oral Anticoagulants vs. Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis

Presenter: Aravdeep Jhand

October 14, 2020

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation TVT 2019

Don’t Stop The Warfarin!: A Case of Left Atrial Appendage Closure Device Thrombus

Presenter: Siri Kadire

June 13, 2019

Presentation TVT 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presenter: DJ Lakkireddy

June 13, 2019

Presentation TCT 2018

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Presenter: Davide Capodanno, Giulio Stefanini, Freek W.A. Verheugt

September 23, 2018

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Presentation TCT 2017

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Samir R. Kapadia, David J. Moliterno

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Presenter: Brij Maini, Petr Neuzil, Grzegorz Smolka, MD

October 31, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation LAA 2017

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

Presenter: Gregg W. Stone

July 21, 2017

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation ESC 2016

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Presenter: Andreas Goette

August 30, 2016

Advertisement

TCT 449: Direct Oral Anticoagulants vs. Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Reversal Strategies for Warfarin and NOACs: The Essentials

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Don’t Stop The Warfarin!: A Case of Left Atrial Appendage Closure Device Thrombus

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content